A pilot study of low-dose recombinant human granulocyte-macrophage colony-stimulating factor in chronic neutropenia.
Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) is under investigation for the treatment of a wide range of haematological disorders. At commonly used doses of > 120 micrograms/m2/d, extramedullary toxicity is common. We report the effects of low-dose (LD) rhGM-CSF in patients with chronic neutropenia related to HIV infection, myelodysplastic syndrome and idiopathic neutropenia. Nine patients with a mean pre-treatment neutrophil count of 0.6 x 10(9)/l (range 0.2-1.4 x 10(9)/l) received daily rhGM-CSF at doses of between 5 and 15 micrograms/m2. Eight patients responded with a mean post-treatment ANC of 3.2 x 10(9)/l (range 1.9-4.6 x 10(9)/l). There was no significant therapy-related morbidity. We conclude that in chronic neutropenia, LD rhGM-CSF is an acceptable treatment which has important cost/benefit implications.
Department of Haematological Medicine, King's College School of Medicine and Dentistry, London.
R S
RS
Kaczmarski
A
A
Pozniak
A
A
Lakhani
E
E
Harvey
G J
GJ
Mufti
D000328:Adult; D002908:Chronic Disease; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000150:complications; D009503:Neutropenia / Q000209:etiology / Q000628:therapy*; D010865:Pilot Projects; D011994:Recombinant Proteins / Q000627:therapeutic use; D013997:Time Factors
D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor